Market Research Report
Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions
|Published by||DelveInsight Business Research LLP||Product code||740511|
|Published||Content info||281 Pages
Delivery time: 1-2 business days
|Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions|
|Published: November 1, 2018||Content info: 281 Pages||
The Oncology market is the most lucrative in the overall therapeutic segment. Up to now, effective cancer medications have probably guaranteed the highest returns for pharmaceutical manufacturers. The market is poised to continue to show strong growth, with an incredible sales rate of oncological therapies, driven by components such as aging population and changes in lifestyle that predispose to diseases. Personalised medicines such as Immuno-checks, gene therapy and T cell therapy are the fastest growing segments within the oncology field and the growth is likely to continue.
Gene Therapy in Oncology is a growing segment in Oncology sector and hold huge promise for the future of cancer therapy. This is due to advances in genomics that add to this positive outlook for cancer patients and genetic modification methods, reinforcing this progress. All cancers represent a certain degree of genetic or hereditary link. As a result of this, small pharmaceutical companies with an emphasis on the improvement of particular, novel innovations may at first focus on a particular growth subtype, yet additionally represents a huge opportunity of being funded through partnership or being acquired by an active portfolio player.
The report “Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions” includes Comprehensive Insights on Cancer Gene Therapy by Market Trends, Competitive Landscape, Clinical Trials, Regulatory Considerations, Potential Geographies Licensing Opportunities, Top Cancer Indications, Vectors (Viral, Non-Viral, Engineered nucleases) and Advancements in Technology. It provides information across the entire gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, and funding and licensing opportunities. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies in a demographic presentation view.
It has covered ~50 gene therapies covering 34 Pharmaceutical companies. Studies have been performed for approximately 60+ specific indications under Oncology. The Companies are utilizing 26 different technology platforms which have own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 82% for viral vectors, 11% for the Non-Viral vectors and 7% for the Bacterial vectors.